NASDAQ$FULC
Fulcrum Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Fulcrum Therapeutics reported financial results for the first quarter of 2024 and provided a business update.
Fulcrum Therapeutics reported its Q1 2024 financial results, highlighting a collaboration agreement with Sanofi for losmapimod, progress in the Phase 3 REACH trial for FSHD, and the appointment of Patrick Horn as Chief Medical Officer. The company's cash position was $213.3 million as of March 31, 2024, with a pro forma cash position of $293.3 million including the Sanofi upfront payment.
- Entered into a collaboration and license agreement with Sanofi for losmapimod development and commercialization outside the U.S.
- On track to report topline data for the Phase 3 REACH trial of losmapimod in FSHD in the fourth quarter of 2024.
- Appointed Patrick Horn as Chief Medical Officer.
- Cash, cash equivalents, and marketable securities were $213.3 million as of March 31, 2024, with a pro forma amount of $293.3 million inclusive of the Sanofi upfront payment.
Headline financials
Revenue & EPS history
Fulcrum Therapeutics · Revenue · Quarterly
$0
Forward guidance
Based on current operating plans, Fulcrum expects that its cash, cash equivalents, and marketable securities as of March 31, 2024, together with the $80.0 million upfront payment to be received from Sanofi, will be sufficient to fund its operating requirements into 2027.
Tailwinds
- Cash runway extended into 2027.
- Upfront payment of $80.0 million from Sanofi.
- Potential for additional $975.0 million in regulatory and sales-based milestones from Sanofi.
- Tiered royalties starting in the low-teens of annual net sales of losmapimod outside the U.S. from Sanofi.
- Global development costs will be equally shared between Fulcrum and Sanofi.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+5.2%
Avg return
Earnings day
+6.3%
Avg return
5 days after
+12.3%
Avg return
30 days after
62%
16 / 26 earnings
Positive
+142.5%
Q2 2021
Best reaction
-54.6%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -21.1% | -23.0% | -36.3% | |
| Q3 2025 | -6.6% | -9.8% | +9.4% | |
| Q1 2025 | +13.8% | +39.0% | +78.6% | |
| Q4 2024 | +0.0% | -3.0% | -16.5% | |
| Q3 2024 | -8.8% | -16.8% | +8.8% | |
| Q2 2024 | +7.1% | +0.6% | +1.7% | |
| Q1 2024 | +5.9% | +1.1% | +3.2% | |
| Q4 2023 | +6.1% | +12.9% | -3.0% | |
| Q3 2023 | +16.2% | -2.5% | +38.2% | |
| Q2 2023 | +3.4% | +5.5% | +49.7% | |
| Q1 2023 | +16.2% | -0.6% | -7.6% | |
| Q4 2022 | -28.0% | -36.6% | -62.0% | |
| Q3 2022 | +23.9% | +27.3% | +9.4% | |
| Q2 2022 | +8.4% | -6.2% | +7.1% | |
| Q1 2022 | -12.5% | -4.1% | -3.8% | |
| Q4 2021 | +17.4% | +37.8% | +113.9% | |
| Q3 2021 | -2.3% | -4.9% | -31.5% | |
| Q2 2021 | +142.5% | +175.3% | +233.9% | |
| Q1 2021 | +4.1% | +3.7% | -13.2% | |
| Q4 2020 | -17.7% | -17.4% | -17.8% | |
| Q3 2020 | +8.6% | +16.9% | +22.3% | |
| Q2 2020 | -54.6% | -55.5% | -54.7% | |
| Q1 2020 | +7.9% | +18.9% | +16.5% | |
| Q4 2019 | -2.2% | -27.8% | -49.4% | |
| Q3 2019 | +1.3% | +27.7% | +48.9% | |
| Q2 2019 | +7.2% | +6.1% | -25.5% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro